{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:40:41Z","timestamp":1781649641595,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.urolonc.2022.02.016","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T19:01:54Z","timestamp":1648321314000},"page":"345.e1-345.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-2185","authenticated-orcid":false,"given":"Stephen B.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Fero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giri","family":"Movva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Baillargeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Chamie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.02.016_bib0001","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0002","doi-asserted-by":"crossref","first-page":"23047","DOI":"10.18632\/oncotarget.25198","article-title":"Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma","volume":"9","author":"Momota","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0003","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/end.2008.0251","article-title":"What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival","volume":"23","author":"Pak","year":"2009","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0004","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupret","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0006","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0007","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0009","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jncimonographs\/lgu018","article-title":"Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies","volume":"2014","author":"Weir","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0010","unstructured":"Health Care Cost Institute. Health care cost and utilization report: Analytic methodology. Available at:https:\/\/healthcostinstitute.org\/annual-reports\/2016-health-care-cost-and-utilization-report%20Accessed%20Spetember%201,%202021; 2016 Accessed September 01, 2021."},{"key":"10.1016\/j.urolonc.2022.02.016_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.4372","article-title":"Comparison of costs of radical cystectomy vs trimodal therapy for patients with localized muscle-invasive bladder cancer","volume":"154","author":"Williams","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0012","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.euf.2016.04.008","article-title":"Underutilization of radical cystectomy among patients diagnosed with clinical stage T2 muscle-invasive bladder cancer","volume":"3","author":"Williams","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0013","article-title":"Zip code census file for SEER-medicare patients","year":"2015","journal-title":"Inf Manage Services Inc"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0014","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0015","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1200\/JCO.2010.31.1217","article-title":"Cost implications of the rapid adoption of newer technologies for treating prostate cancer","volume":"29","author":"Nguyen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urology.2006.03.062","article-title":"Clinical model of lifetime cost of treating bladder cancer and associated complications","volume":"68","author":"Avritscher","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0017","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0018","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2009.08.004","article-title":"Clinical audit in gynecological cancer surgery: development of a risk scoring system to predict adverse events","volume":"115","author":"Kondalsamy-Chennakesavan","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0019","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2016.03.028","article-title":"Perioperative outcomes, health care costs, and survival after robotic-assisted versus open radical cystectomy: A national comparative effectiveness study","volume":"70","author":"Hu","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jval.2010.10.006","article-title":"Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003","volume":"14","author":"Cipriano","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0022","unstructured":"Yang D, Dalton JE A unified approach to measuring the effect size between two groups using SAS\u00ae. Available at:https:\/\/www.semanticscholar.org\/paper\/A-unified-approach-to-measuring-the-effect-size-two-Yang-Dalton\/6cf4bd36ca4c90006a5d6563f646a391c255581b; 2012 Accessed September 01, 2021."},{"key":"10.1016\/j.urolonc.2022.02.016_bib0023","unstructured":"UroGen Pharma. Press Release: UroGen Pharma receives FDA fast track designation for MitoGel(TM) for the treatment of upper tract urothelial carcinoma (UTUC). Available at:https:\/\/investors.urogen.com\/news-releases\/news-release-details\/urogen-pharma-receives-fda-fast-track-designation-mitogeltm; 2017 Accessed September 01, 2021."},{"key":"10.1016\/j.urolonc.2022.02.016_bib0024","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care-a health economics approach: An ISPOR Special Task Force Report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","article-title":"Health technology assessment with diminishing returns to health: The generalized risk-adjusted cost-effectiveness (GRACE) approach","volume":"24","author":"Lakdawalla","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMp0904131","article-title":"A strategy for health care reform\u2014toward a value-based system","volume":"361","author":"Porter","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.urology.2021.06.053","article-title":"Endoscopic management of low-grade upper tract urothelial carcinoma: Characterizing the long-term burden of care in comparison to radical nephroureterectomy","volume":"159","author":"Shenhar","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2022.02.016_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25810","article-title":"Assessment of financial toxicity among older adults with advanced cancer","volume":"3","author":"Arastu","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922000709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922000709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:22Z","timestamp":1761042322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922000709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1078143922000709"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}